Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB1211 plus atezolizumab in advanced NSCLC
NCT05240131Phase 2Active, not recruiting
- Sponsor
- Galecto, Inc.
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of selvigaltin in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Galecto, Inc. Primary endpoints: Safety and tolerability of GB1211 in combination with atezolizumab at 3 weeks, Safety and tolerability of GB1211 in combination with atezolizumab compared to atezolizumab and placebo at 12 weeks and 2 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
selvigaltin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05240131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240131.